<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" xml:lang="en" article-type="abstract"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Eur Psychiatry</journal-id><journal-id journal-id-type="iso-abbrev">Eur Psychiatry</journal-id><journal-id journal-id-type="publisher-id">EPA</journal-id><journal-title-group><journal-title>European Psychiatry</journal-title></journal-title-group><issn pub-type="ppub">0924-9338</issn><issn pub-type="epub">1778-3585</issn><publisher><publisher-name>Cambridge University Press</publisher-name><publisher-loc>Cambridge, UK</publisher-loc></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmc">PMC11862520</article-id><article-id pub-id-type="doi">10.1192/j.eurpsy.2024.230</article-id><article-id pub-id-type="other">O0108</article-id><article-id pub-id-type="pii">S092493382400230X</article-id><article-categories><subj-group subj-group-type="heading"><subject>Abstract</subject></subj-group><subj-group subj-group-type="section"><subject>Oral Communication</subject></subj-group></article-categories><title-group><article-title>Preliminary data from the CONNEX-X extension trial examining the long-term safety of iclepertin in patients with schizophrenia who completed Phase III CONNEX trials</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Reuteman-Fowler</surname><given-names>C.</given-names></name><xref rid="aff0361" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Blahova</surname><given-names>Z.</given-names></name><xref rid="aff0362" ref-type="aff">
<sup>2</sup>
</xref><xref rid="cor0091" ref-type="corresp">
<sup>*</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Marder</surname><given-names>S.</given-names></name><xref rid="aff0363" ref-type="aff">
<sup>3</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Ikezawa</surname><given-names>S.</given-names></name><xref rid="aff0364" ref-type="aff">
<sup>4</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Falkai</surname><given-names>P.</given-names></name><xref rid="aff0365" ref-type="aff">
<sup>5</sup>
</xref></contrib></contrib-group><aff id="aff0361">
<sup>1</sup>Boehringer Ingelheim RCV GmbH &#x00026; Co. KG, <city>Ridgefield</city>, <state>CT</state>, <country>United States</country></aff><aff id="aff0362">
<sup>2</sup>Boehringer Ingelheim RCV GmbH &#x00026; Co. KG, <city>Vienna</city>, <country>Austria</country></aff><aff id="aff0363">
<sup>3</sup>Department of Psychiatry and Behavioral Sciences, David Geffen School of Medicine, <city>Los Angeles</city>, <state>CA</state>, <country>United States</country></aff><aff id="aff0364">
<sup>4</sup>Department of Psychiatry, International University of Health and Welfare, Mita Hospital, <city>Minato-ku
</city>, <state>Tokyo</state>, <country>Japan</country></aff><aff id="aff0365">
<sup>5</sup>Clinic of Psychiatry and Psychotherapy, Ludwig Maximilians University Munich, <city>Munich</city>, <country>Germany</country></aff><author-notes><corresp id="cor0091"><label>*</label>Corresponding author.</corresp></author-notes><pub-date publication-format="electronic" date-type="collection" iso-8601-date="2024-04"><month>4</month><year>2024</year></pub-date><pub-date pub-type="epub"><day>27</day><month>8</month><year>2024</year></pub-date><volume>67</volume><issue seq="205">Suppl 1</issue><issue-title content-type="special_issue">Abstracts of the 32nd European Congress of Psychiatry</issue-title><fpage>S91</fpage><lpage>S92</lpage><permissions><copyright-statement>&#x000a9; The Author(s) 2024</copyright-statement><copyright-year>2024</copyright-year><copyright-holder>The Author(s)</copyright-holder><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (<uri xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</uri>), which permits unrestricted re-use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><self-uri xlink:title="pdf" xlink:href="S092493382400230Xa.pdf"/><abstract><sec id="sec0544"><title>Introduction</title><p>Cognitive impairment associated with schizophrenia (CIAS) is an important unmet need as there are no effective treatments available. Iclepertin (BI 425809), a glycine transporter-1 inhibitor, has been shown to improve CIAS in Phase II trials, and Phase III trials are underway.</p></sec><sec id="sec0545"><title>Objectives</title><p>The ongoing CONNEX-X extension study aims to collect additional safety data relating to iclepertin treatment in patients with CIAS.</p></sec><sec id="sec0546"><title>Methods</title><p>CONNEX-X (NCT05211947/1346-0014) is a multinational, multicentre, open-label, single-arm extension study in patients with CIAS who completed 26 weeks of treatment (iclepertin 10 mg or placebo) in one of 3 Phase III CONNEX parent trials (NCT04846868/1346-0011, NCT04846881/1346-0012, NCT04860830/1346-0013). An estimated 1400 clinically stable outpatients will be treated (iclepertin 10 mg daily) for 1 year, irrespective of previous treatment (iclepertin/placebo). Patients are excluded if any of the following circumstances occur during the parent study and up to Visit 1 of CONNEX-X: suicidal behaviour or ideation (type 5 on the Columbia-Suicide Severity Rating Scale), diagnosis with moderate/severe substance use disorder, diagnosis other than schizophrenia (according to Diagnostic and Statistical Manual of Mental Disorders &#x02013; Fifth Edition), development of any condition preventing participation, a haemoglobin level decrease (&#x0003e;25% or &#x0003c;100g/L from baseline in parent trial) or haemoglobinopathies. The primary endpoint is the occurrence of treatment-emergent adverse events. The secondary endpoints include change from baseline (CfB) in Clinical Global Impressions-Severity (CGI-S) and CfB in haemoglobin. Further efficacy endpoints include CfB in MATRICS Consensus Cognitive Battery (MCCB) overall composite T-score, CfB in Schizophrenia Cognition Rating Scale total score and CfB in Virtual Reality Functional Capacity Assessment Tool (VRFCAT) total times.</p></sec><sec id="sec0547"><title>Results</title><p>Currently, 460 patients have been enrolled and randomised from the parent trials with 0% screening failures (-80% roll-over rate, 30 August 2023). Current study status, including recruitment, screening failures and data collection experiences, are presented.</p></sec><sec id="sec0548"><title>Conclusions</title><p>Patient enrolment rates from the CONNEX trials to the CONNEX-X open-label extension study are stable. CONNEX-X will allow the exploration of long-term safety, as well as descriptive analyses of cognitive and functional endpoints of iclepertin in the treatment of CIAS.</p></sec><sec id="sec0549"><title>Funding</title><p>Boehringer Ingelheim</p></sec><sec id="sec0550"><title>Disclosure of Interest</title><p>C. Reuteman-Fowler Employee of: Boehringer Ingelheim Pharmaceuticals, Inc., Z. Blahova Employee of: Boehringer Ingelheim RCV GmbH &#x00026; Co. KG, S. Marder Consultant of: Boehringer Ingelheim Pharma GmbH, Merck, Biogen and Sunovion, S. Ikezawa Consultant of: Boehringer Ingelheim Pharma GmbH, Lundbeck, Takeda Pharma, Sumitomo Dainippon Pharma, Employee of: International University of Health and Welfare, Mita Hospital, Tokyo, Japan, P. Falkai Consultant of: Boehringer Ingelheim Pharma GmbH, Boehringer Ingelheim Pharma advisory board</p></sec></abstract><counts><page-count count="2"/></counts></article-meta></front></article>